OnKure reprices underwater stock options for CEO and other executives
The board approved a repricing that cut the exercise price on eligible options to $4.14 per share, with a retention condition tied to continued service.
SEC filing
Latest
3 stories
Wednesday, August 12
Tuesday, August 4
OnKure amends ATM prospectus, drops Form S-3 offering cap
OnKure Therapeutics said it is no longer subject to a rule limiting how much stock it can sell under its existing $100 million at-the-market program with Leerink Partners.
SEC filing
OnKure reports Q2 2026 results, keeps IND filings for two PI3Kα drugs on track for 1H 2027
OnKure said OKI-355 and OKI-345 remain in IND-enabling work with FDA submissions planned for the first half of 2027, and cash of $176.4 million is expected to fund operations into 2029.
SEC filing